Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier for advanced OPTIONS screeners and volatility tools. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or

Amryt Pharma Plc ADR (AMYT)

Amryt Pharma Plc ADR (AMYT)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Chiesi Farmaceutici S.p.A. Completes Acquisition of Amryt Pharma Plc

/PRNewswire/ -- Chiesi Farmaceutici S.p.A. ("Chiesi"), an international, research-focused biopharmaceuticals and healthcare group, today announced the...

AMYT : 14.70 (+0.07%)
AMYT Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Amryt Pharma Plc Is Fair to Shareholders

Halper Sadeh LLC, an investor rights law firm, is investigating whether the sale of Amryt Pharma Plc (NASDAQ: AMYT) to Chiesi Farmaceutici S.p.A. is fair to Amryt shareholders. Per the terms of the proposed...

AMYT : 14.70 (+0.07%)
AMRYT PHARMA INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Amryt Pharma Plc - AMYT

Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Amryt Pharma Plc (NasdaqGS: AMYT) to Chiesi...

AMYT : 14.70 (+0.07%)
Why Shares of Amryt Pharma Jumped This Week

A takeover bid by an Italian pharmaceutical and healthcare company boosted Amryt's shares.

AMYT : 14.70 (+0.07%)
AMRYT PHARMA INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Amryt Pharma Plc - AMYT

Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Amryt Pharma Plc (NasdaqGS: AMYT) to Chiesi...

AMYT : 14.70 (+0.07%)
SHAREHOLDER ALERT: The M&A Class Action Firm Announces the Investigation of Amryt Pharma Plc - AMYT

/PRNewswire/ -- Juan Monteverde, founder and managing partner of the class action firm Monteverde & Associates PC (the "M&A Class Action Firm"), a national...

AMYT : 14.70 (+0.07%)
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates AMYT, CINC, ALBO

/PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws...

AMYT : 14.70 (+0.07%)
CINC : 29.06 (-0.48%)
ALBO : 44.15 (-0.23%)
AMYT Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Amryt Pharma Plc Is Fair to Shareholders

Halper Sadeh LLC, an investor rights law firm, is investigating whether the sale of Amryt Pharma Plc (NASDAQ: AMYT) to Chiesi Farmaceutici S.p.A. is fair to Amryt shareholders. Per the terms of the proposed...

AMYT : 14.70 (+0.07%)
Amryt to Report Q2 2022 Results on August 4, 2022

DUBLIN, Ireland, and Boston MA, July 21, 2022, Amryt (Nasdaq: AMYT) a global, commercial-stage biopharmaceutical company dedicated to acquiring, developing...

AMYT : 14.70 (+0.07%)
Amryt Receives Orphan Drug Designation from the FDA for Mycapssa® (oral octreotide) for the Treatment of Carcinoid Syndrome

Amryt Receives Orphan Drug Designation from the FDA for Mycapssa® (oral octreotide) for the Treatment of Carcinoid Syndrome DUBLIN, Ireland, and Boston...

AMYT : 14.70 (+0.07%)

Barchart Exclusives

2 Overlooked Energy Dividend Stocks to Buy This November
EQT Corporation and Exelon Corporation are two overlooked energy dividend stocks that offer attractive opportunities for investors in November, with EQT's strong recovery momentum in natural gas and Exelon's steady growth and commitment to clean energy making them well-positioned for long-term gains. Read more
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar